May 15, 2019
Stealth BioTherapeutics Reports First Quarter 2019 Financial Results And Recent Business Highlights
Apr 25, 2019
Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy
Apr 16, 2019
Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial
Apr 04, 2019
Stealth BioTherapeutics Reports Fiscal Year 2018 Financial Results and Recent Business Highlights
Apr 02, 2019
Stealth BioTherapeutics to Present at H.C. Wainwright Global Life Sciences Conference
Dec 10, 2018
Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy
Nov 15, 2018
NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders
Nov 09, 2018
2018 Drug Development Pipeline Review for Optic Nerve Disorders (Optic Neuropathy, Glaucoma, LHON and Optic Neuritis)
Oct 29, 2018
Unapproved Therapies Cause Significantly More Patient Injuries Than Reported by Cell Therapy Clinics
Oct 10, 2018
Dante Labs Expands Its Full DNA Test With Proprietary Analysis of Mitochondrial and Neurological Diseases
Oct 10, 2018
NeuroVive Receives KL1333 Clinical Trial Regulatory Approval
Jun 18, 2018
NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics
Jun 18, 2018
Stealth BioTherapeutics Announces $100M Financings to Advance Clinical Development of Elamipretide and Pipeline
Apr 30, 2018
Stealth BioTherapeutics Granted Orphan Drug Designation of Elamipretide for Treatment of Leber's Hereditary Optic Neuropathy
Mar 06, 2018
Stealth BioTherapeutics Completes Enrollment of Study for the Treatment of Barth Syndrome
Nov 27, 2017
Stealth BioTherapeutics Granted Fast Track Designation for the Treatment of Barth Syndrome
Nov 06, 2017
Stealth BioTherapeutics Initiates Phase 3 Study of Elamipretide in Patients with Primary Mitochondrial Myopathy
Oct 02, 2017
Stealth BioTherapeutics Granted Orphan Drug Designation of Elamipretide for Treatment of Patients with Primary Mitochondrial Myopathy
Aug 23, 2017
Altered Mitochondria Associated with Increased Autism Risk
Aug 07, 2017
Stealth BioTherapeutics Announces New Appointments to its Board of Directors